NHS Hospitals to Trial Groundbreaking AI Tool for Diagnosing Prostate Cancer
The National Health Service (NHS) is set to test a cutting-edge artificial intelligence tool that aims to help diagnose and treat prostate cancer. The £1.9 million Vanguard Path study, which will run for three years, will utilize the ArteraAI Prostate Biopsy Assay to analyze digitized biopsy images and produce a personalized risk score.
Researchers at the University of Oxford have already demonstrated the tool's potential in clinical trials, identifying high-risk prostate cancer patients who would benefit from the drug abiraterone. However, experts now hope to expand its use to predict treatment outcomes for less aggressive forms of prostate cancer and monitor patients without immediate intervention.
The trial will involve over 4,000 men, with biopsies used to test the tool's accuracy in predicting treatment responses. Experts believe that the AI-powered assessment could help reduce under- and over-treatment by providing a more personalized approach to patient care.
"We're investing in a digital NHS because we know technology can transform cancer care," said Ashley Dalton, Minister for Public Health and Prevention. "This groundbreaking research has the potential to improve patient outcomes and save lives."
The study will first use existing biopsy samples from diagnosed patients before testing the tool at three NHS sites. Clinicians will be given access to the AI-generated risk scores alongside the traditional assessment, allowing researchers to gauge the impact of the tool on treatment decisions.
Prostate Cancer UK director Matthew Hobbs expressed optimism about the trial's potential: "If and when this gets implemented, you could use one tool irrespective of where you are on the aggressiveness scale, to make a very clinically and life-enhancingly important decision for each of those men."
The National Health Service (NHS) is set to test a cutting-edge artificial intelligence tool that aims to help diagnose and treat prostate cancer. The £1.9 million Vanguard Path study, which will run for three years, will utilize the ArteraAI Prostate Biopsy Assay to analyze digitized biopsy images and produce a personalized risk score.
Researchers at the University of Oxford have already demonstrated the tool's potential in clinical trials, identifying high-risk prostate cancer patients who would benefit from the drug abiraterone. However, experts now hope to expand its use to predict treatment outcomes for less aggressive forms of prostate cancer and monitor patients without immediate intervention.
The trial will involve over 4,000 men, with biopsies used to test the tool's accuracy in predicting treatment responses. Experts believe that the AI-powered assessment could help reduce under- and over-treatment by providing a more personalized approach to patient care.
"We're investing in a digital NHS because we know technology can transform cancer care," said Ashley Dalton, Minister for Public Health and Prevention. "This groundbreaking research has the potential to improve patient outcomes and save lives."
The study will first use existing biopsy samples from diagnosed patients before testing the tool at three NHS sites. Clinicians will be given access to the AI-generated risk scores alongside the traditional assessment, allowing researchers to gauge the impact of the tool on treatment decisions.
Prostate Cancer UK director Matthew Hobbs expressed optimism about the trial's potential: "If and when this gets implemented, you could use one tool irrespective of where you are on the aggressiveness scale, to make a very clinically and life-enhancingly important decision for each of those men."